2022
DOI: 10.1038/s41541-022-00485-x
|View full text |Cite
|
Sign up to set email alerts
|

Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies

Abstract: The mRNA vaccine platform has offered the greatest potential in fighting the COVID-19 pandemic owing to rapid development, effectiveness, and scalability to meet the global demand. There are many other mRNA vaccines currently being developed against different emerging viral diseases. As with the current COVID-19 vaccines, these mRNA-based vaccine candidates are being developed for parenteral administration via injections. However, most of the emerging viruses colonize the mucosal surfaces prior to systemic inf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
22
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 38 publications
(22 citation statements)
references
References 170 publications
0
22
0
Order By: Relevance
“…GBP510/AS03 vaccination was shown here to be highly protective against challenge with Delta SARS-CoV-2 in rhesus macaques, correlating with antibody responses. Neutralizing antibody responses have been considered a correlate of protection for other COVID-19 vaccines, but further research of local immune responses is warranted 11,12,31,39 . In particular, future research should focus on the induction of mucosal antibody responses [40][41][42][43][44] as well as resident cellular responses [40][41][42][43][44][45] .…”
Section: Discussionmentioning
confidence: 99%
“…GBP510/AS03 vaccination was shown here to be highly protective against challenge with Delta SARS-CoV-2 in rhesus macaques, correlating with antibody responses. Neutralizing antibody responses have been considered a correlate of protection for other COVID-19 vaccines, but further research of local immune responses is warranted 11,12,31,39 . In particular, future research should focus on the induction of mucosal antibody responses [40][41][42][43][44] as well as resident cellular responses [40][41][42][43][44][45] .…”
Section: Discussionmentioning
confidence: 99%
“…These achievements were reached through successive and iterative progress, both in mRNA delivery through LNP vehicles and in mRNA design. It has been widely documented that mRNA vaccine technology is easy- and fast-to-produce, cost-effective, and highly versatile, offering new perspectives to treat a large number of pathologies [ 43 , 44 , 45 ]. As global warming offers more suitable conditions to improve pathogen dissemination, human adaptation, and epidemic outbreak, mRNA vaccines will become a unique tool to propose a fast preventive deployment strategy onsite to interfere with new fast-adapting and -spreading human pathogens [ 46 , 47 ].…”
Section: Discussionmentioning
confidence: 99%
“…Cationic cyclodextrin-PEI conjugated to the IVT mRNA encoding OVA, significantly promoted nasal mRNA vaccine delivery in mice after nasal vaccination and also stimulated DC maturation and migration, which further enhanced the humoral and cellular immune responses [ 182 ]. The advent of mRNA vaccines against SARS-CoV-2 may further facilitate the development of lipid nanoparticle nasal mucosal RNA vaccines against respiratory infectious diseases [ 183 ]. This suggests that liposomes could be used for delivering several forms of antigens.…”
Section: Nasal Vaccine Adjuvantsmentioning
confidence: 99%